Navigation Links
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
Date:2/23/2013

SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. In prespecified subgroups from two paired clinical trials, tiotropium delivered once daily via the Respimat® inhaler improved lung function and asthma control, as defined by a decrease in asthma exacerbations or worsening of asthma, in patients with poorly controlled asthma, irrespective of their allergic status. Patients included in the study remained symptomatic despite current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

"Patients with asthma may respond differently to treatment based on their allergic status, therefore it is important to investigate new therapies in both allergic and non-allergic patients," said Mark Vandewalker , MD, director, Clinical Research of the Ozarks, Columbia, Missouri. "The results of these trials show that tiotropium provides additional bronchodilation and reduces exacerbation rates in asthmatics who are uncontrolled on current therapy with at least ICS/LABA regardless of their allergic status, thus demonstrating its potential benefit for patients who need additional asthma control."

The two PrimoTinA-asthma™ studies were replicate double-blind parallel-group trials including asthma patients with post-bronchodilator FEV1 less than 80 percent predicted and asthma control questionnaire score of greater than or equal to 1.5, while on at least high dose ICS/LABA. A total of 912 patients were randomized to receive tiotropium 5 mcg or placebo in addition to usual care for 48 weeks. In addition to ICS/LABA, patients in the trials were permitted to receive additional background t
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
...  GenVec, Inc. (Nasdaq: GNVC ) will report financial ... 2011 on Thursday, March 15, 2012, before the U.S. financial ... and conference call at 10:00 a.m. EDT to discuss the ... outlook. To listen to the live conference ...
... release of System 7 – the next generation of heavy ... such as hip and knee replacements. System 7 offers the ... and highest performing power tool system ever from Stryker. ... heavy duty power tools in 1982, and has built a ...
Cached Medicine Technology:GenVec to Release Fourth Quarter and Year-End 2011 Financial Results and Conduct a Conference Call on March 15, 2012 2Stryker Launches Next Generation Heavy Duty Surgical Power Tools 2
(Date:6/19/2013)... Middle market merger and acquisition (M&A) ... as cash rich buyers seek to place their capital ... M&A transactions have a good deal in common. The ... history and quality of the target company’s earnings. Potential ... due diligence involves a middle market company, whose value ...
(Date:6/19/2013)... Faith4Kidz is starting a new fundraising effrt to ... like help showing support for kids to learn how to ... Check out the website, http://www.gracenfaith.com to see Faith4Kidz ... white and blue stars as a symbol of our country ... well as the stars we should encourage our children to ...
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 ... Pharmacy and Drug Retailer industry has been growing ... $42.7 billion in 2013. Many factors have supported the ... demand for drugs retailed by drugstores; relatively higher drug ... , Additionally, the government's support for the development of ...
(Date:6/18/2013)... June 19, 2013 Consumer injury attorney ... other law firms have launched a new website for ... by dialysis. The website is http://www.DialysisLawsuitAttorneys.com . , ... to begin offering legal services to people who may ... and NaturaLyte, or who may have suffered injuries due ...
(Date:6/18/2013)... June 19, 2013 oBand Surgery Centers, ... are holding complimentary weight loss seminars in Los Angeles ... can be accessed at their official website. oBand Surgery ... recovery time. Their highly skilled panel of surgeons and ... , A senior executive working with oBand Surgery ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2
... EVVV ),a global endovascular device company, today ... and Chief Financial Officer, effective January,19, 2009. Mr. ... President and Chief Financial Officer effective January 19, 2009. ... than 15 years of experience in the medical,device industry ...
... a flatter, tighter stomachSHELBY TOWNSHIP, Mich., Jan. 9 ... tummy tuck without the downtime!The traditional tummy tuck, or ... want to regain a flat stomach after weight fluctuations ... solves the problem of the loose abdominal skin and ...
... trends and growth predictions of industry.NEW YORK, Jan. 9 ... and the Advanced Medical Technology Association (AdvaMed) today announced ... industry experts on the major trends and growth in ... survey aims to generate new data points on geography, ...
... also rule out this additional measure, study suggests , , ... levels in an asthmatic child,s breath every day does ... a new study shows. , Nitric oxide (NO) amounts ... symptoms or even an attack. But a 30-week Dutch ...
... Jan. 9 A study published today in The,Journal ... the mean annual price tag for lupus - including ... - was,nearly $20,000 per patient. The mean cost climbed ... by the kidney disease nephritis, as it,often is. That,s ...
... kids in five-county regionPHILADELPHIA, Jan. 9 An inherent ... more opportunities and a better life than their parents ... obesity among children continues to rise, and the current ... country,s history to have a shorter lifespan than their ...
Cached Medicine News:Health News:ev3 Inc. Appoints Shawn McCormick as New Sr. Vice President and Chief Financial Officer 2Health News:Doctors at Allure Medical Spa Are Getting the Results of a Tummy Tuck Without the Downtime 2Health News:Gerson Lehrman Group Partners With AdvaMed for Survey on Medical Device Industry 2Health News:Gerson Lehrman Group Partners With AdvaMed for Survey on Medical Device Industry 3Health News:Nitric Oxide Monitoring of Little Benefit for Kids' Asthma 2Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 2Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 2Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 4
Inquire...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
20L...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: